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ABSTRACT
Food is an important source of human aluminium (Al) exposure and regular consumption of
foods containing Al-based food additives may result in high Al intakes above health-based
tolerable intakes. However, some additives are Al salts with low solubility, and little is known
about bioavailability of Al in these additives. We investigated urine Al concentrations in healthy
adult volunteers (N = 18, women/men) before (base-line) and after 7 days of ingestion of
pancakes with a low Al content (median: <0.5 mg Al/kg) and high Al content (median:
860 mg/kg). The high-Al pancakes contained the common additive sodium aluminium phos-
phate (SALP). The participants did not know if the pancakes contained SALP or not during the
experiment. After adjusting for creatinine content of the urine samples, median base-line Al
concentrations before pancake ingestion were in the range 30–40 µmol Al/mol creatinine.
Urine Al concentrations after ingestion of low-Al pancakes (average intake: <0.042 Al mg/day)
did not differ significantly from the base-line levels. After ingestion of high-Al pancakes (72 mg
Al/day) the median Al concentration in urine was more than 2-fold higher than at the base-line
sampling before the high-Al pancake ingestion. At the end of the experiment the volunteers
ingested an Al-containing antacid (Al-OH, 1800 mg Al/day) for 7 days as a positive control of Al
absorption. This caused a 10-fold increase in median urine Al concentration compared to base-
line. Our results strongly suggest that Al in the form of SALP in a pancake mix is bioavailable for
absorption in humans, which should be taken into account in risk assessment of Al in food in
countries with a high use of SALP as a food additive.
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Food is an important source of human aluminium
(Al) exposure. Duplicate diet studies, total diet stu-
dies and market basket surveys, from Japan,
Australia, North America and Europe, have reported
average Al intakes ranging from 2.4 to 13mg/day for
adults (Krewski et al. 2007; EFSA 2008; JECFA
2012). The solubility of Al at neutral pH is low,
thus contributing to a low bioavailability for intest-
inal Al absorption (<1%) (Krewski et al. 2007).
Concomitant presence of organic acids in the intest-
inal lumen, however, increases the solubility and
bioavailability of Al for absorption (Krewski et al.
2007). The absorbed fraction is relatively effectively
excreted within a few days in the urine, although
a part of absorbed Al has a very long half-life (years)
(Greger and Sutherland 1997; Priest 2004). Al accu-
mulates and causes neurotoxic effects and bone
toxicity in patients with impaired kidney function
when exposed to Al in dialysis water (Wills and
Savory 1989; Rob et al. 2001). Al neurotoxicity and
bone toxicity are suggested problems in preterm
infants exposed to Al in intravenous-feeding solu-
tions (Bishop et al. 1997; Poole et al. 2008). The
European Food Safety Authority (EFSA) has pro-
posed a tolerable intake of Al in food of 1 mg Al/kg
body weight/week (TWI), whereas the Joint FAO/
WHO Expert Committee on Food Additives esti-
mated the TWI to 2 mg/kg/w (EFSA 2008; JECFA
2012). The tolerable intake was in both cases based
on animal studies showing neuro-toxicity, embryo-
toxicity, testis-toxicity and toxicity on the develop-
ing nervous system. The EFSA expert group con-
cluded that the EFSA TWI is likely to be exceeded by
a significant part of the European population (EFSA
2008).
CONTACT Anders Glynn anders.glynn@slu.se Department of Biomedical Sciences and Veterinary Public Health, Swedish University of Agricultural
Sciences (SLU), P.O. Box 7028, Uppsala SE-75007, Sweden
FOOD ADDITIVES & CONTAMINANTS: PART A
https://doi.org/10.1080/19440049.2019.1626998
© 2019 Taylor & Francis Group, LLC
In 2013 EFSA published a report on human
dietary exposure to Al-containing food additives.
It was concluded that regular consumption of
foods with Al additives would result in Al intakes
well above the TWI (EFSA 2013). However, little
is known about the bioavailability of Al in addi-
tives when present in foods. A study of oral bioa-
vailability of Al in the food additive acidic
sodium aluminium phosphate (SALP) in rats
fed SALP-containing biscuits reported that bioa-
vailability of Al in SALP (0.1%) was less than
bioavailability of Al in drinking water (0.3%)
(Yokel and Florence 2006). To our knowledge
no study has investigated the degree of intestinal
absorption of the food additive Al in human
subjects from the general population during reg-
ular consumption of Al additive-containing
foods. A better knowledge about the Al absorp-
tion from additives in such foodstuffs would
greatly improve the risk assessment of the use of
Al additives.
We have previously shown that Al concentra-
tion in urine is a sensitive marker of intestinal Al
absorption from an over-the-counter antacid
(Al-OH) (Gräske et al. 2000). In the current
study we investigated urine Al concentrations in
18 healthy volunteers before and after 7 days of
daily consumption of pancakes made of pancake
mixes containing no Al additives or an Al addi-
tive declared as sodium aluminium phosphate
(SALP). The aim was to determine if consump-
tion of Al additive-containing pancakes resulted
in increased urine Al concentrations above back-
ground, as a measure of Al absorption.
Materials and methods
Study participants
Healthy adult volunteers, 9 women and 9 men
(mean age: 44 years, range: 25–60 years)
employed by the Swedish National Food Agency
and living in the City of Uppsala, Sweden, were
recruited for the study. Participants reported in
a questionnaire that they had not used medicinal
drugs containing Al during 30 days before the
experiment started, and did not take drugs that
interact with Al. Participants had not been vacci-
nated at least 2 months before the experiments.
The study was approved by the Ethics Committee
of the Medical Faculty at Uppsala University,
Uppsala, Sweden.
Experimental design
Study participants daily (in the morning) ingested
the test meals for 7 days (test period), with periods
of no consumption of at least 7 days between test
periods (rest periods) (Figure 1). As a positive
control of Al exposure, an Al-containing antacid
(Al-OH) was also taken daily for 7 days after a rest
Figure 1. Experimental design. Baseline urine sampling for Al
analyses took place in the morning before the start of the
7-day ingestion of pancakes and antacid. Test sampling of
urine took place directly after the last ingestion of pancakes
and antacid in the morning of the 7th day of ingestion.
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period with no pancake ingestion of at least
7 days. The test periods occurred in the sequence
pancakes without Al additive (low-Al), pancakes
containing Al additive (high-Al) and antacid. The
participants did not know if the pancakes con-
tained Al or not during the experiment. Spot
urine samples (approx. 15 ml) were taken by
the participants before and after each test period.
Al-free plastic tubes (Labora, Sollentuna, Sweden)
were used. The baseline samples were taken at the
first toilet visit in the morning of the first day of
the test periods. On day 7 of the test periods
a urine sample was similarly taken in the morning
after the final ingestion of pancakes or antacid
(test sampling). The urine samples were acidified
by adding 0.5 ml sub-boiled distilled nitric acid to
10 ml of urine and stored frozen (−20°C) until
analysis. Special precautions were taken to prevent
extraneous Al contamination.
Pancakes and antacid
Two different types of pancake mixes were used,
one for which no Al-containing additives were
declared on the package and one for which use
of SALP was declared. The content of several
packages of each mix were mixed together before
preparation of the batter. Pancake batter was pre-
pared as instructed on the packages and pancakes
were cooked in a cast iron skillet with indentations
to allow for seven small pancakes to be made at
once. The median weight of the pancakes was 21 g
(range 15–29 g, N = 26). The median Al concen-
tration in the low-Al pancakes was <0.5 mg Al/kg
(range:<0.5–4.6 mg/kg, N = 10) and in the high-Al
pancakes 860 mg/kg (range: 750–1200 mg/kg,
N = 10). Pancakes were randomly sampled for
Al analyses, and the remaining pancakes were
randomly placed in plastic bags (4 in each) and
stored at −20°C until distributed to the study
participants. The study participant consumed 4
pancakes per day for 7 days, resulting in an aver-
age Al intake of 72 mg/day from high-Al pancakes
and <0.042 mg/day from low-Al pancakes.
An over-the-counter antacid was used as a positive
control of Al absorption. According to the product
data sheet the 10 ml suspension contained 588 mg Al
as Al-OH, and users were recommended to take
5–10 ml when necessary during episodes of acid
reflux. The study subjects were asked to take 3 doses
of 10 ml suspension per day for 7 days, one dose in
the morning, at lunch and in the evening. Such
a dosing resulted in an Al intake of 1800 mg Al/day
Analyses of urine creatinine and aluminium
Urine creatinine concentrations were determined
at the University Hospital, Uppsala, Sweden by an
accredited routine laboratory analytical technique.
Analyses were performed by a kinetic colorimetric
assay on a Hitachi 717 clinical chemistry analyzer,
using the HiCo Creatinine (CREA) kit (Boehring
Mannheim, Mannheim, Germany).
Aluminium in pancakes and urine were analyzed
blinded at ALS Scandinavia AB, Luleå, Sweden, by
inductively coupled plasma – sector field mass spec-
trometry (ICP-SFMS, Element 1, Thermo Finnigan),
using modified USEPA Methods 200.7 and 200.8.
Pancake samples (0.3–0.5 g) were digested in a com-
mercial microwave oven in capped Teflon vessels
using nitric acid (s.p, 5 ml) and hydrogen peroxide
(0.5 ml). Urine samples (0.5 ml) were diluted with
0.1 ml nitric acid (s.p). Before analysis pancake and
urine samples were diluted with Millipore water and
an internal standard solution with 5 ppm Lu was
added. For both pancakes and urine the sample solu-
tions were compared to certified elemental standard
solutions traceable to NIST (National Institute of
Standards and Technology). The isotopes Al27 and
Lu175 were monitored in medium resolution mode
with six scans of each peak. The quantification limit
(LOQ) for Al in pancakes was 0.5 mg Al/kg and in
urine 2 µg Al/l. LOQs for both matrices were deter-
mined as 10 times the standard deviation of seven
method blanks. A method blank was included in the
analyses of both the pancake and urine samples,
introduced from the first step of the sample prepara-
tion. The Al concentration in the urine blank was
1.29 µg Al/l. The concentration in method blank
was not subtracted from themeasured concentrations
in the samples. A reference material, Seronorm
(urine, lot 0511545) was analyzed together with the
urine samples and the measured concentration was
113 µg Al/l (certified concentration 88–112 ng Al/l).
The expected concentration for the reference
material was 112 ng Al/l, based on the laboratory´s
control card results for the Al analyses in urine.
The laboratory participated in QMEQAS (Quebec
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Multi-elemental External Quality Assessment
Scheme). The z-scores for the laboratory´s results in
the three QMEQAS rounds for 2011, when the urine
samples were analyzed, ranged between −1.08 to 0.29
(satisfactory).
Calculations and statistics
In the statistical analyses Al concentrations in urine
were expressed as µmol Al/mol creatinine. Al con-
centrations below LOQ were set to ½LOQ.
Differences in urine Al concentrations between sam-
pling occasions were tested with the Mann-Whitney
U test. Spearman´s correlation coefficients were cal-
culated in the analyses of relations between Al con-
centrations at different sampling occasions. In this
case Al urine data were not transformed. Level of
significance was set to p ≤ 0.05.
Results
Only one urine sample had an Al concentration
below LOQ (<2 µg Al/l). The median Al concen-
tration in urine was 7.2 µg/l (range: 2.0–18 µg/l)
at the first baseline measurement, 6.9 µg/l (range:
2.7–25 µg/l) after ingestion of low-Al pancakes,
5.7 µg/l (range: <2–18 µg/l) at the second baseline
measurement, 14 µg/l (range: 2.7–43) after
ingestion of high-Al pancakes, 12 µg/l (range:
2.6–26 µg/l) after the third baseline measure-
ment, and 110 µg/l (range: 28–500 µg/l) after
the antacid ingestion.
After adjusting for creatinine content of the urine
samples, median base-line Al concentrations after the
rest periods were in the range 30–40 µmol Al/mol
creatinine (Figure 2). Al concentrations after inges-
tion of low-Al pancakes did not differ significantly
from the base-line 1 concentrations. After ingestion
of high-Al pancakes for 7 days the median Al con-
centration in urine was more than 2-fold higher
(67 µmol Al/mol creatinine) than in base-line 2 sam-
ples taken in the morning before the start of ingestion
of the pancakes (26 µmol Al/mol creatinine)
(p≤ 0.05) (Figure 2). Antacid dosing for 7 days caused
a 10-fold higher median Al concentration in urine
compared with the median concentration at base-line
3 (p ≤ 0.05) (Figure 2).
Creatinine-adjusted Al concentrations in sam-
ples from base-line 1 were significantly correlated
with concentrations after ingestion of no-Al pan-
cakes (r = 0.64, p = .005), and with concentrations
in base-line 2 samples (Spearman´s r = 0.66,
p = .003). The correlation between no-Al pancakes
concentrations and base-line 2 was weaker
(r = 0.39, p = .106), and correlations between base-
line 3 and the other background samples varied
(r = −0.007–0.48, p = .977–0.045).
Discussion
Our results show that daily consumption of 4
small pancakes containing the Al additive SALP
(860 mg Al/kg pancake) by 18 volunteers resulted
in a significant increase in urine Al concentrations
compared to the base-line Al concentrations in the
same subjects before consumption of the pan-
cakes. This shows that the Al intake from the
pancakes (72 mg Al/day) was high enough to
Figure 2. Al concentrations (median, max) in spot urine samples of
18 healthy volunteers. Samples were taken before and after con-
sumption pancakes with no Al additive, pancakes with the Al
additive SALP, and an Al-containing antacid for 7 days. Baseline
sample 1 was taken in the morning before the start of no Al
pancake ingestion. Baseline sample 2 was taken at least 7 days
after the end of ingestion of no Al pancakes, in the morning before
start of ingestion of pancakes with Al (SALP). Baseline 3 sample was
taken after a rest period of at least 7 days, in the morning before
start of ingestion of Al-containing antacid. Test samples were taken
in the morning directly after the last ingestion of no Al pancakes, Al
pancakes and antacid during the test period. *p ≤ 0.05, between
baseline 2 and Al pancake samplings, and between baseline 3 and
Al antacid samplings (Mann-Whitney U test, N = 18).
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cause an increased Al absorption, thus strongly
suggesting that the Al in SALP was bioavailable
for intestinal absorption.
This is to our best of knowledge the first study
to experimentally investigate bioavailability of Al
additives in humans consuming food available on
the market. The additive in the pancake mix was
declared as SALP. This additive is in many coun-
tries used either in an acidic form in for instance
baking powder for special uses or in a basic form
as an emulsifier in processed cheese (Yokel et al.
2008). Although not stated on the pancake mix
package, the additive used was most probably the
acidic form of the additive, as a component of
the leveling agent in the pancake mix. Within
the European Union, acidic SALP (E541) is only
authorized for use in certain layered sponge cakes
with a maximum limit of 400 mg Al/kg in the
sponge cake parts, and a recent risk assessment
concluded that SALP is of no safety concern in the
current authorized use (EFSA 2018). The median
Al concentrations in the pancakes containing the
Al additive in our study was twice as high as the
maximum limit for layered sponge cakes. The mix
was produced in the United States (US), where
SALP is authorized for a much wider use than
within the EU, for instance in self-rising flours
and meals (FDA 2018). As a consequence,
human exposure to acidic SALP is therefore
most probably higher in the US than in Europe.
In a US study from 2005, it was estimated that
SALP in pancake and waffle mixes could provide
up to 180 mg Al per serving (Saiyed and Yokel
2005). In our study, the breakfast with 4 small
pancakes (about 80 g) provided on average
74 mg Al per serving, which is less than half of
the estimated intakes from a serving of waffles and
pancakes (Saiyed and Yokel 2005).
In Europe, total dietary exposure to Al has been
estimated as 1.6 to 13 mg/day, corresponding to
0.2 to 1.5 mg/kg body weight per week for adults
with a body weight of 60 kg (EFSA 2008). For
children the intake is higher due to a higher con-
sumption of food per kg body weight than among
adults (EFSA 2008). Duplicate diet studies from
Japan, India and Taiwan have indicated similar
average daily intakes among adults as in Europe
(JECFA 2012). Inter-individual variation of intake
may however be large as our study suggests that
consumption of pancakes containing SALP may
result in a daily intake more than 5-fold higher
than the average daily intake. Assuming a body
weight of 60 kg, regular consumption of the
SALP-containing pancakes for breakfast may con-
tribute about 8 mg Al/kg body weight/week, which
is considerably higher than the TWIs published by
EFSA and JECFA (1 and 2 mg/kg/w, respectively)
(EFSA 2008; JECFA 2012). For children, most
likely consuming more pancakes per kg body
weight than adults, the intake would be even
higher than for adults.
Absorbed Al after ingestion is mainly excreted
by the kidneys in humans. Our adult study partici-
pants had a median urine Al concentration at
base-line 1 and 2, and after ingestion of pancakes
with low Al content, of <10 µg/L, with a max of
<30 µg/L). Median concentrations are in the same
range as recently reported for healthy adults from
France and the UK (Morton et al. 2014; Nisse et al.
2017), but lower than reported from the Czech
Republic and China (Frankova et al. 2016; Wang
et al. 2016; Lu et al. 2016). It is difficult to measure
Al in biological samples from humans correctly,
due to the high risk of contamination during sam-
pling, sample storage and sample preparation
(Michalke et al. 2018), making comparisons
between studies difficult. In our study, the similar-
ity of concentrations between the base-line sam-
plings and sampling after ingestion of low-Al
pancakes suggests that the study subjects did not
intentionally or un-intentionally change their habits
in such a way that general Al exposure was signifi-
cantly affected during the pancake ingestion peri-
ods. The subjects were blinded to the Al content of
the pancakes, which further assured that the results
of the study was not biased by changes in habits by
the subjects during pancake ingestion. We observed
a relatively strong relation between urine Al con-
centrations at the 2 first base-line samplings and
the sampling after ingestion of low-Al pancakes.
This further suggests a stable background Al expo-
sure among participants. The weaker correlations
between concentrations in these samples and those
in the base-line samples after high Al-pancake
ingestion period may be due to a remaining influ-
ence of Al ingestion on urine concentrations in
some subjects after the relatively short rest period
(minimum 7 days).
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Oral bioavailability of different forms of Al has
in animal experiments been determined to be
0.025–1.5% (Willhite et al. 2014). In humans,
using 26Al methodology, oral bioavailability ran-
ged from 0.002% to 1% (Priest 2004). A study of
bioavailability of 26Al in rats fed 26Al-SALP-
containing biscuits (1–2% SALP) reported a 26Al
bioavailability of 0.1% (Yokel and Florence 2006).
In 2011 EFSA evaluated a study of bioavailability
of ingested 26Al-labelled Al and Al compounds in
the rat, made available by the industry (EFSA
2011). Bioavailability was studied by determining
the ratio of the fraction of 26Al left in the carcass
7 days after oral administration of the 26Al-
labelled compound over the fraction of carcass
26Al left 7 days after intravenous administration
(iv) of 26Al-labelled aluminium citrate. In the
study, the fraction of absorption was estimated
to range from 0.025% (Al hydroxide) to 0.21
(Al sulphate). For SALP bioavailability was
<0.024% (EFSA 2011).
The design of our study did not make it possible to
determine the oral bioavailability of Al from SALP.
We can only do a rough calculation of the percentage
of Al excreted in urine after ingestion of SALP, which
was estimated to be about 0.04% of the daily Al dose
from the high-Al pancakes. This estimate is based on
the assumption that the creatinine-adjusted Al con-
centrations in the spot urine samples are representa-
tive of concentrations in 24-h urine samples. The
median 24-h Al urinary excretion after the 7-day
consumption the high-Al pancakes was estimated to
be approximately 0.9 µmol Al, using the median spot
urine Al concentration (67 nmol/mmol creatinine)
after high-Al pancake ingestion and average 24-h
creatinine excretion in adults of approximately
13 mmol (average for men and women) (Bingham
et al. 1988; Alexandrov et al. 2018). After subtraction
of the average base-line Al excretion (0.34 µmol/24 h),
and assuming that about 50% of the absorbed Al dose
is excreted within 24 h (Talbot et al. 1995), the excre-
tion of 0.56 µmol Al/24 h during 2 days (1.1 µmol Al)
represents approximately 0.04% of the daily Al dose
from the pancakes (2.7 mmol).
At the end of the study period the participants
ingested an over-the-counter antacid containing
Al-hydroxide for 7 days, resulting in an Al dose
of 1800 mg/day (66 mmol). After this exposure the
average urine Al concentration was about 10 times
higher than at the background samplings, showing
a large increase in Al absorption. In an earlier
study (Gräske et al. 2000) healthy adults took the
same antacid dose daily for 6 weeks, resulting in
median concentrations of Al in urine after 2, 4,
and 6 weeks of 334–419 nmol/mmol creatinine,
which was similar to the median concentration
found in the present study after 1 week of Al
antacid dosing (440 nmol/mmol creatinine). This
suggests a stabilization of Al excretion already
after 1 week of antacid dosing. Using the same
assumption as in the calculations of bioavailability
of Al in SALP, urinary excretion of antacid Al was
estimated to about 0.017% of the daily Al dose
from the antacid.
In Sweden, and most probably also in many other
countries, Al antacids are regarded as safe for treat-
ment of heartburn during pregnancy. Heartburn is
common in pregnancy and symptomsmay persist for
several months from the end of the first trimester
(Richter 2005). Al antacids are commonly taken in
connection to meals and there are components in
food, such as low-molecular-weight organic acids,
that substantially increase the bioavailability of Al
from antacids (Slanina et al. 1986; Walker et al.
1990). Taken together, our results and the results
from animal studies regarding transfer of Al from
themother to the fetus (Domingo et al. 2000), strongly
suggest that long-term use of Al antacids during
pregnancy may increase the risk of Al accumulation
in the growing fetus. Since studies have shown that
gestational Al exposure of animals causes develop-
mental effects of the offspring, and that Al antacids
can be used by pregnant women without professional
medical control, the safety of Al antacids during preg-
nancy can be questioned (Reinke et al. 2003).
Riihimäki and Aitio (Riihimaki and Aitio 2012) pro-
posed an action limit for urine Al of 80 µg/L in
occupational workers, based on reports of impaired
cognition in Al welders with many years of exposure.
This action limit is lower than the median Al concen-
trations observed among our healthy volunteers tak-
ing the antacid as recommended on the package.
Conclusion
Our study shows that daily ingestion of pancakes
containing the food additive SALP for a week causes
an increased Al excretion in urine, strongly
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suggesting that Al in SALP is bioavailable for intest-
inal absorption. Long-term daily consumption of
products containing similar levels of SALP as in
the pancakes may thus cause an increased Al accu-
mulation in the body above background. Since back-
ground exposure to Al is close or above currently
accepted tolerable intakes, this additional exposure
is of concern. An even higher concern is the avail-
ability of over-the-counter drugs with a very high Al
content, especially if used over an extended time
period by women during pregnancy.
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